Scout Bio Expands Gene Therapy Collaboration with the University of Pennsylvania Via Next-Generation Vector Technologies Partnership agreement includes exclusive rights in animal health to novel viral vector capsid and expands additional option rights to novel capsidsNext-generation novel adeno-associated viral (AAV)...

Scout Bio Named Best New Start-Up for 2021 PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Scout Bio, a biotechnology company focused on one-time AAV gene therapies for major chronic pet health conditions, received top honors as the Best...

Scout Bio Initiates Multi-Center Clinical Study of Gene Therapy for Chronic Arthritis Pain In Cats - First vectorized antibody gene therapy to be studied in pets- Strong initial in-species data support therapeutic profile of one-time gene therapy designed for long-term pain management- Novel...

Scout Bio Closes $33 Million Series B2 Financing to Advance its Portfolio of Single Injection Gene Therapy Technology for the Treatment of Chronic Diseases in Pets - Proceeds to support advancing single injection Adeno-Associated Viral (AAV) vector therapeutics targeting chronic companion animal diseases including diabetes, pain, and anemia associated with...

4BIO Capital’s review of AAV gene therapy clinical trials published in Nature Reviews Drug Discovery Press Release 4BIO Capital’s review of AAV gene therapy clinical trials published in Nature Reviews Drug Discovery Systematic review and meta-analysis of 149 clinical trials of AAV-based gene...